業績

2021年

1. Manabe S, Takashima H, Ohnuki K, Koga Y, Tsumura R, Iwata N, Wang Y, Yokokita T, Komori Y, Usuda S, Mori D, Haba H, Fujii H, Yasunaga M, Matsumura Y. Stabilization of an ²¹¹At-labeled antibody with sodium ascorbate. ACS Omega, 2021 (in press).

2. Sekiguchi M, Kakugawa Y, Ikematsu H, Hotta K, Konda K, Tanaka Y, Takamaru H, Yamada M, Sakamoto T, Saito Y, Imai K, Ito S, Koga Y, Iwasaki M, Murakami Y, Matsuda T. Risk stratification score improves sensitivity for advanced colorectal neoplasia in colorectal cancer screening: the oshima study workgroup. Clin Transl Gastroenterol 12(3): e00319, 2021.

3. Takashima H, Koga Y, Manabe S, Ohnuki K, Tsumura R, Anzai T, Iwata N, Wang Y, Yokokita T, Komori Y, Mori D, Usuda S, Haba H, Fujii H, Matsumura Y, Yasunaga M. Radioimmunotherapy with an ²¹¹At-labeled anti-tissue factor antibody protected by sodium ascorbate. Cancer Sci 112(5):1975-1986, 2021.

4. Shiraishi T, Ikeda K, Tsukada Y, Nishizawa Y, Sasaki T, Ito M, Kojima M, Ishii G, Tsumura R, Saijou S, Koga Y, Yasunaga M, Matsumura Y. High expression of TMEM180, a novel tumour marker, is associated with poor survival in stage III colorectal cancer. BMC Cancer 21(1):302, 2021.

5. Tsumura R, Anzai T, Manabe S, Takashima H, Koga Y, Yasunaga M, Matsumura Y. Antitumor effect of humanized anti tissue factor antibody drug conjugate in a model of peritoneal disseminated pancreatic cancer. Oncol Rep 45(1):329-336, 2021.

6. Kamakura D, Asano R, Kawai H, Yasunaga M. Mechanism of action of a T cell-dependent bispecific antibody as a breakthrough immunotherapy against refractory colorectal cancer with an oncogenic mutation. Cancer Immunol Immunother 70:177-188, 2021.
   

2020年

1. Yasunaga M. Antibody therapeutics and immunoregulation in cancer and autoimmune disease. Semin Cancer Biol 64:1-12, 2020.

2. Takashima H, Koga Y, Tsumura R, Yasunaga M, Tsuchiya M, Inoue T, Negishi E, Harada M, Yoshida S, Matsumura Y. Reinforcement of antitumor effect of micelles containing anticancer drugs by binding of an anti-tissue factor antibody without direct cytocidal effects. J Control Release 323:138-150, 2020.

3. Tsumura R, Koga Y, Hamada A, Kuwata T, Sasaki H, Doi T, Aikawa K, Ohashi A, Katano I, Ikarashi Y, Ito M, Ochiai A. The report of the use of patient-derived xenograft models in the development of anticancer drugs in Japan. Cancer Sci 111(9):3386-3394, 2020.

4. Matsumura Y. Cancer stromal targeting therapy to overcome the pitfall of EPR effect. Adv Drug Deliv Rev 154-155:142-150, 2020.

5. Numasawa K, Hanaoka K, Saito N, Yamaguchi Y, Ikeno T, Echizen H, Yasunaga M, Komatsu T, Ueno T, Miura M, Nagano T, Urano Y. A fluorescent probe for rapid, high-contrast visualization of folate-receptor-expressing tumors in vivo. Angew Chem Int Ed Engl 59(15):6015-6020, 2020.
   

2019年

1. Yasunaga M, Saijou S, Hanaoka S, Anzai T, Tsumura R, Matsumura Y. Significant antitumor effect of an antibody against TMEM180, a new colorectal cancer-specific molecule. Cancer Sci 110(2):761-770, 2019.

2. Tsumura R, Manabe S, Takashima H, Koga Y, Yasunaga M, Matsumura Y. Evaluation of the antitumor mechanism of antibody-drug conjugates against tissue factor in stroma-rich allograft models. Cancer Sci 110(10):3296-3305, 2019.

3. Anzai T, Matsumura Y. Topological analysis of TMEM180, a newly identified membrane protein that is highly expressed in colorectal cancer cells. Biochem Biophys Res Commun 520(3):566-572, 2019.

4. Koga Y, Ochiai A. Systematic review of patient-derived xenograft models for preclinical studies of anti-cancer drugs in solid tumors. Cells 8(5):418, 2019.

5. Manabe S, Yamaguchi Y, Matsumoto K, Fuchigami H, Kawase T, Hirose K, Mitani A, Sumiyoshi W, Kinoshita T, Abe J, Yasunaga M, Matsumura Y, Ito Y. Characterization of antibody products obtained through enzymatic and non-enzymatic glycosylation reactions with a glycan oxazoline and preparation of homogeneous antibody-drug conjugate via Fc N-glycan. Bioconjug Chem 30:1343-1355, 2019.

6. Sugyo A, Aung W, Tsuji A, Sudo H, Takashima H, Yasunaga M, Matsumura Y, Saga T, Higashi T. Antitissue factor antibodymediated immunoSPECT imaging of tissue factor expression in mouse models of pancreatic cancer. Oncol Rep 41:2371-2378, 2019.

7. Koganemaru S, Kuboki Y, Koga Y, Kojima T, Yamauchi M, Maeda N, Kagari T, Hirotani K, Yasunaga M, Matsumura Y, Doi T. U3-1402, a novel HER3-targeting antibody–drug conjugate, for the treatment of colorectal cancer. Mol Cancer Ther 18:2043-2050, 2019.

8. Yamazaki N, Koga Y, Matsumura Y. MicroRNA analysis of colorectal cancer using fecal and tissue samples. RNA & DISEASE 6:e1592, 2019. 
   

2018年

1. Yasunaga M, Manabe S, Furuta M, Ogata K, Koga Y, Takashima H, Nishida T, Matsumura Y. Mass spectrometry imaging for early discovery and development of cancer drugs. AIMS Md Sci 5:162-180, 2018.

2. Tsumura R, Manabe S, Takashima H, Koga Y, Yasunaga M, Matsumura Y. Influence of the dissociation rate constant on the intra-tumor distribution of antibody-drug conjugate against tissue factor. J Control Release 284:49-56, 2018.

3. Fuchigami H, Manabe S, Yasunaga M, Matsumura Y. Chemotherapy payload of anti-insoluble fibrin antibody-drug conjugate is released specifically upon binding to fibrin. Sci Rep 8:14211, 2018.

4. Aung W, Tsuji A, Sugyo A, Takashima H, Yasunaga M, Matsumura Y, Higashi T. Near-infrared photoimmunotherapy of pancreatic cancer using an indocyanine green-labeled anti-tissue factor antibody. World J Gastroenterol 24:5491-5504, 2018.

5. Yamazaki S, Higuchi Y, Ishibashi M, Hashimoto H, Yasunaga M, Matsumura Y, Tsuchihara K, Tsuboi M, Goto K, Ochiai A, Ishii G. Collagen type I induces EGFR-TKI resistance in EGFR-mutated cancer cells by mTOR activation through Akt-independent pathway. Cancer Sci 109:2063-2073, 2018.
   

2017年

1. Yasunaga M, Manabe S, Matsumura Y. Immunoregulation by IL-7R-targeting antibody-drug conjugates: overcoming steroid-resistance in cancer and autoimmune disease. Sci Rep 7:10735, 2017.

2. Takashima H, Tsuji A, Saga T, Yasunaga M, Koga Y, Kuroda J, Yano S, Kuratsu J, Matsumura Y. Molecular imaging using an anti-human tissue factor monoclonal antibody in an orthotopic glioma xenograft model. Sci Rep 7:12341, 2017.

3. Yasunaga M, Manabe S, Tsuji A, Furuta M, Ogata K, Koga Y, Saga T, Matsumura Y. Development of antibody-drug conjugates using DDS and molecular imaging. Bioengineering 4:E78, 2017.

4. Yamazaki N, Koga Y, Taniguchi H, Kojima M, Kanemitsu Y, Saito N, Matsumura Y. High expression of miR-181c as a predictive marker of recurrence in stage II colorectal cancer. Oncotarget 8(4):6970-6983, 2017.

5. Fukuoka S, Kojima T, Koga Y, Yamauchi M, Komatsu M, Komatsuzaki R, Sasaki H, Yasunaga M, Matsumura Y, Doi T, Ohtsu A. Preclinical efficacy of Sym004, novel anti-EGFR antibody mixture, in esophageal squamous cell carcinoma cell lines. Oncotarget 8:11020-11029, 2017.